We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Premaitha | LSE:NIPT | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.10 | 9.00 | 9.20 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
05/2/2018 07:18 | More good news. | curlly | |
24/1/2018 10:28 | Re RNS - "UK High Court grants right to appeal" "Illumina had sought an immediate injunction against the IONA® test in the UK" "Premaitha was ordered to pay interim costs to Illumina of an amount in the region of £1.5m." "Premaitha agreed to pay 10% of UK revenues earned from the Hearing date" "We anticipate the appeal cycle will take at least 12 months" "We have attempted to engage Illumina into meaningful settlement discussions both before and since the November judgment" And from 2 days back - 22nd Jan - Secured loan facility agreement with Thermo Fisher - provides up to £2.1m to fund costs related to the ongoing Illumina litigation... secured on the shares of the Company's Taiwanese subsidiary undertaking So most of that utilised already to pay interim costs into escrow with ongoing appeal case legal fees at ?/month. Given the above costs I don't anticipate any change to cashburn for the current half year previously averaging around £700k/month - see below ...........1H 2H16 1H 2H17 1H18 Revenue.. 0.6 1.8 1.5 1.6 2.7* Cashburn. 4.4 3.8 3.7 4.2 4.4 Creditors 1.2 2.1 2.6 3.5 4.8 Borrowings. 0 1.4 2.6 4.3 8.1 * inc Yourgene 1H18 Revenue increase of £1.26m almost entirely attributable to Yourgene acquisition (see Yourgene acquisition announcement) | dj trading | |
24/1/2018 09:48 | Agreed Stuart, it has been the uncertainty of unknown costs more than the diminishing importance of the UK market that's held this back.The RNS provides clarity as much as it can, with clear guidance going forward. | rathean | |
24/1/2018 08:27 | I looked at the title of the RNS and my heart sunk to be honest but having read and digested it, I feel very positive and I’m confident the market will do too. The interim payment removes huge ambiguity about potential settlement costs and the monthly allocation of 10% of UK revenues is sensible and allows transparency on potential costs moving forward. What’s really exciting to me is the worldwide business we are engaged in, which is an ever growing percentage of our total portfolio and with breakeven surely imminent now in the next quarter or so, the future looks extremely exciting. I bought at 30p and have been on the rollercoaster ever since, and finally I can see light at the end of the tunnel and an upside. I’m sticking as a LTH. | stuartc2015 | |
24/1/2018 08:16 | Very good news, had these on my watchlist for a while but dipped in this morning at 4.88. Confidence in their overseas expansion and I suspect an out of court settlement is more likely now leave to appeal has been granted. | rathean | |
24/1/2018 07:35 | VERY encouraging RNS IMO. | small crow | |
24/1/2018 07:23 | We was at 8p in November so will we go back up to that?? | curlly | |
24/1/2018 07:18 | Well there you go, looks like excellent news to me. | timojelly | |
24/1/2018 05:49 | Well, whatever today's possible outcome, let's just get on with it. | timojelly | |
22/1/2018 10:19 | Excellent news - it strengthens NIPT'S negotiating stance immeasurably. Bargain rating down here - priced to go bust when they are expanding across the globe gangbusters! | philjeans | |
22/1/2018 08:40 | PJ1, Given the Ariosa v Illumina ongoing case in California, I wouldn't be so sure. Some big players (Roche) still want a dog in this fight! | small crow | |
22/1/2018 08:38 | The only benefit is that it now shows Illumina NIPT are funded to fight more, not that they will fight, which I hope they do not. I suspect it's a ruse to facilitate negotiations moving forward. | pj 1 | |
22/1/2018 07:10 | timojelly Not necessarily, if non-UK revenues continue to grow and if we can see signs of any promised non-NIPT tests, these legal issues may become sideshow .... and back to 30P+? | small crow | |
12/1/2018 11:54 | thinkBIG? why waste them i have papered my walls with the ones i have saves a hell of a lot of money buying rolls wallpaper LOL | humphries1 | |
12/1/2018 10:53 | Smoke & Mirrors Monkster.... | small crow | |
12/1/2018 10:49 | must be game over here now surely | the monkster | |
12/1/2018 08:31 | Both my buys showing as sells. Keep the faith. Happy New Year all. | ngen yap | |
10/1/2018 23:32 | Not looking good going busy 100% | thinkbig? | |
10/1/2018 15:18 | It won't be known as Premaitha a year from now I expect! | hjb1 | |
10/1/2018 14:37 | Agreed. Further dilution and I suspect a year from now we'll be at the 1p level. | the monkster | |
10/1/2018 14:37 | Agreed. Further dilution and I suspect a year from now we'll be at the 1p level. | the monkster |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions